Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome
Information source: Bayside Health
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Marfan Syndrome
Intervention: Coversyl (perindopril) (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Bayside Health Official(s) and/or principal investigator(s):
Bronwyn A Kingwell, PhD, Principal Investigator, Affiliation: Baker Heart Research Institute
Summary
The purpose of this research is to assess the effects of a drug called perindopril on the
aorta in people known to have Marfan Syndrome. The aorta is the major artery of the body that
comes out of the heart and supplies blood to the body. We know that in people with Marfan
Syndrome, the aorta is stiff and this stiffness results in its enlargement over many years.
This enlargement of the aorta can be very serious. We know from treatment of other heart
conditions that drugs of the same type as perindopril reduce stiffness of the arteries. This
type of drug has never been tried in people with Marfan Syndrome.
Clinical Details
Official title: The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.
Study design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: aortic root diameter
Secondary outcome: arterial stiffness
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age 18-40
- Diagnosis of Marfan Syndrome, on the basis of the Ghent Criteria
Exclusion Criteria:
- Age <18, >40
- Women of child-bearing potential not on adequate contraception
- Serum creatinine of >0. 11
- A history of intolerance to ACEI
- Patients on angiotensin receptor blockers
- Blood pressure >140/90mmHg
- History of previous aortic surgery
Locations and Contacts
Additional Information
Starting date: January 2004
Ending date: September 2006
Last updated: June 12, 2007
|
